AtriCure, Inc.
Description
AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
About
CEO
Mr. Michael H. Carrel
Employees
1,200
Instrument type
Common Stock
Sector
Healthcare
Industry
Medical Instruments & Supplies
MIC code
XNMS
Address
7555 Innovation Way, Mason, OH 45040, United States
×
![Enlarged Chart]()
Oscillators
Invalid data format
Summary
Invalid data format
Moving Averages
Invalid data format
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Oct 27, 2025 | — | — | — | — |
| Jul 28, 2025 | — | — | — | — |
| Apr 29, 2025 | — | — | — | — |
| Feb 13, 2025 | -0.23 | — | — | — |
| Oct 30, 2024 | -0.19 | -0.17 | 0.02 | -10.53% |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 7 | — | 8 |
| Average estimate | — | -0.21 | — | -0.62 |
| Low estimate | — | -0.24 | — | -0.68 |
| High estimate | — | -0.16 | — | -0.53 |
| Last year EPS | — | -0.25 | — | -0.74 |
[stock_revenue_estimate]
Growth estimates
Current qtr
30.030%
Next qtr. (Mar 2025)
16.750%
Current year
1.030%
Next year (Dec 2025)
16.160%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total reported revenue | 399.25M | 330.38M | 274.33M | 206.53M | 230.81M |
| Cost of revenue | 98.88M | 84.44M | 68.47M | 57.22M | 60.47M |
| Gross profit | 300.37M | 245.94M | 205.86M | 149.31M | 170.34M |
| Operating expense | |||||
| Research & development | 73.92M | 57.34M | 48.51M | 43.07M | 41.23M |
| Selling general and admin | 253.14M | 231.27M | 204.65M | 150.83M | 167.14M |
| Other operating expenses | — | — | — | — | — |
| Operating income | -26.68M | -42.67M | -47.30M | -44.59M | -38.04M |
| Non operating interest income | |||||
| Income | 3.79M | 1.99M | 466,000 | 1.10M | 2.40M |
| Expense | 6.93M | 4.99M | 4.92M | 4.89M | 4.11M |
| Other income expense | -31,000 | -537,000 | 102.13M | 333,000 | 4.76M |
| Pretax income | -29.85M | -46.20M | 50.39M | -48.04M | -35.00M |
| Tax provision | 591,000 | 268,000 | 188,000 | 114,000 | 199,000 |
| Net income | -30.44M | -46.47M | 50.20M | -48.16M | -35.19M |
| Basic EPS | -0.66 | -1.02 | 1.11 | -1.14 | -0.94 |
| Diluted EPS | -0.66 | -1.02 | 1.09 | -1.14 | -0.94 |
| Basic average shares | 46.31M | 45.74M | 45.07M | 42.13M | 37.59M |
| Diluted average shares | 46.31M | 45.74M | 45.07M | 42.13M | 37.59M |
| EBITDA | -8.11M | -29.50M | -36.75M | -33.97M | -26.43M |
| Net income from continuing op. | -30.44M | -46.47M | 50.20M | -48.16M | -35.19M |
| Minority interests | — | — | — | — | — |
| Preferred stock dividends | — | — | — | — | — |
Balance sheet
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 613.93M | 585.45M | 615.31M | 714.54M | 557.88M |
| Current assets | |||||
| Cash | — | — | — | — | — |
| Cash equivalents | — | — | — | — | — |
| Cash and cash equivalents | 84.31M | 58.10M | 43.65M | 41.94M | 28.48M |
| Other short term investments | 52.98M | 63.01M | 75.44M | 202.27M | 53.32M |
| Accounts receivable | 52.50M | 42.69M | 33.02M | 23.15M | 28.05M |
| Other receivables | — | — | — | — | — |
| Inventory | 67.90M | 45.93M | 38.96M | 35.03M | 29.41M |
| Prepaid assets | — | — | 5.00M | 4.35M | 3.90M |
| Restricted cash | — | — | — | — | — |
| Assets held for sale | — | — | — | — | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | 8.56M | 5.48M | 5.00M | 4.35M | 3.90M |
| Non current assets | |||||
| Properties | 27.73M | 25.14M | 24.94M | 20.99M | 24.68M |
| Land and improvements | 1.01M | 1.01M | 1.01M | 502,000 | 502,000 |
| Machinery furniture equipment | 33.92M | 30.44M | 22.52M | 20.59M | 18.52M |
| Construction in progress | 7.33M | 3.91M | 6.00M | 2.07M | 5.71M |
| Leases | — | — | 8.73M | 8.65M | 6.08M |
| Accumulated depreciation | -52.42M | -46.82M | -41.27M | -36.84M | -33.06M |
| Goodwill | 533.55M | 508.90M | 512.55M | 597.76M | 599.44M |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | 63.99M | 39.34M | 42.99M | 128.20M | 129.88M |
| Investments and advances | — | 51.51M | 104.34M | 14.18M | 12.68M |
| Other non current assets | 2.16M | 1.99M | 955,000 | 440,000 | 705,000 |
| Total liabilities | 147.76M | 128.69M | 131.56M | 302.15M | 310.54M |
| Current liabilities | |||||
| Accounts payable | 27.35M | 19.90M | 18.60M | 12.74M | 14.95M |
| Accrued expenses | 2.50M | 3.30M | 2.69M | 7.11M | 27.11M |
| Short term debt | 2.53M | 5.47M | 1.76M | 8.42M | 2.22M |
| Deferred revenue | — | — | — | — | — |
| Tax payable | — | — | 1.45M | 1.26M | 1.66M |
| Pensions | 39.43M | 26.92M | 30.99M | 17.73M | — |
| Other current liabilities | — | 5.47M | 1.76M | — | — |
| Non current liabilities | |||||
| Long term debt | 71.96M | 69.08M | 73.89M | 65.58M | 74.20M |
| Provision for risks and charges | — | — | — | — | — |
| Deferred liabilities | — | — | — | — | — |
| Derivative product liabilities | — | — | — | — | — |
| Other non current liabilities | 1.23M | 1.23M | 1.22M | 187.42M | 186.42M |
| Shareholders equity | |||||
| Common stock | 48,000 | 47,000 | 46,000 | 45,000 | 40,000 |
| Retained earnings | -357.06M | -326.62M | -280.15M | -330.35M | -282.20M |
| Other shareholders equity | -993,000 | -4.10M | -948,000 | 312,000 | -158,000 |
| Total shareholders equity | 466.17M | 456.75M | 483.76M | 412.39M | 247.34M |
| Additional paid in capital | 824.17M | 787.42M | 764.81M | 742.39M | 529.66M |
| Treasury stock | — | — | — | — | — |
| Minority interest | — | — | — | — | — |
Cash flow statement
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||||||||||
| Net Income | -30.44M | -46.47M | 50.20M | -48.16M | -35.19M | -21.14M | -26.89M | -33.34M | -27.21M | -16.21M | -11.46M | -7.53M | -5.46M | -3.79M | -16.49M | -10.17M | -11.25M | -13.72M | -12.68M | -9.45M |
| Depreciation | 14.81M | 11.71M | 10.44M | 9.55M | 9.37M | 8.75M | 9.13M | 9.30M | 6.28M | 4.77M | 2.02M | 1.90M | 1.92M | 2.36M | 2.41M | 2.68M | 2.32M | 1.89M | 1.55M | 962,355 |
| Deferred Taxes | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | 35.73M | 28.77M | 28.08M | 22.64M | 17.98M | 16.50M | 14.62M | 11.70M | 9.00M | 7.57M | 3.08M | 3.47M | 2.94M | 2.77M | 3.89M | 2.67M | — | — | — | — |
| Other Non-Cash Items | 1.99M | 1.25M | -182.43M | 1.50M | -2.42M | -9.64M | -3.81M | 1.19M | 61,000 | -7.82M | 115,000 | 100,000 | 272,000 | 296,000 | 4.05M | 20,440 | 1.76M | 1.13M | — | — |
| Accounts Receivable | -9.87M | -8.99M | -10.09M | 5.09M | -3.20M | -2.84M | -1.46M | -1.98M | -900,000 | -4.17M | -1.25M | -417,000 | -199,000 | -2.30M | -685,986 | 609,337 | -561,132 | -1.78M | 92,432 | -1.89M |
| Accounts Payable | 6.18M | 2.68M | 4.71M | -1.56M | 2.79M | -2.40M | 1.29M | -1.07M | 4.01M | -944,000 | 1.45M | -132,000 | 788,000 | 893,000 | -1.55M | 597,461 | — | — | — | — |
| Other Assets & Liabilities | -26.11M | -9.60M | -7.74M | -5.26M | -7.31M | -382,000 | -4.06M | -110,000 | -3.58M | -4.08M | -3.32M | 724,000 | -1.12M | 25,000 | 1.59M | -1.64M | -1.65M | -517,199 | 750,692 | 1.09M |
| Operating Cash Flow | -7.71M | -20.65M | -106.83M | -16.20M | -18.00M | -11.15M | -11.19M | -14.32M | -12.34M | -20.88M | -9.37M | -1.89M | -855,000 | 257,000 | -6.80M | -5.23M | -9.38M | -13.00M | -10.29M | -9.29M |
| Investing Activities | ||||||||||||||||||||
| Capital Expenditures | -12.00M | -16.88M | -9.75M | -5.26M | -12.14M | -6.21M | -6.38M | -7.69M | -24.00M | -9.13M | -2.82M | -2.96M | -1.43M | -1.81M | -1.36M | -1.75M | -3.04M | -1.66M | -1.95M | -1.51M |
| Net Intangibles | -30.00M | — | — | — | — | — | — | — | — | — | — | — | 300,000 | — | — | — | — | — | — | — |
| Net Acquisitions | — | — | — | — | -17.24M | — | — | — | -7.58M | — | 3.71M | — | — | — | — | -417,292 | -3.34M | — | -6.42M | — |
| Purchase of Investments | — | -24.64M | -173.11M | -227.05M | -73.25M | -106.59M | -16.46M | -28.59M | -19.53M | -41.11M | -21.24M | -9.24M | -12.65M | -11.12M | -8.02M | -1.90M | -8.21M | -6.29M | -6.37M | — |
| Sale of Investments | 63.82M | 85.52M | 206.36M | 75.31M | 100.49M | 27.39M | 26.60M | 24.20M | 40.60M | 19.61M | 6.20M | 9.40M | 16.51M | 9.60M | 1.20M | 8.89M | 5.81M | 8.07M | — | — |
| Investing Cash Flow | 51.82M | 44.01M | 23.50M | -156.20M | -2.15M | -85.40M | 3.76M | -12.08M | -10.50M | -30.62M | -10.44M | -2.80M | 2.42M | -3.34M | -2.17M | -1.17M | -8.79M | 114,643 | -14.74M | -1.51M |
| Financing Activities | ||||||||||||||||||||
| Long-Term Debt Issuance | — | — | 5.00M | — | 20.50M | 17.38M | — | 25.00M | 340,000 | 3.70M | — | 10.00M | 7.50M | — | 6.50M | 6.00M | — | — | — | — |
| Long-Term Debt Payments | -992,000 | -899,000 | -5.82M | -667,000 | -629,000 | -1.76M | -1.69M | -439,000 | -263,000 | -6.38M | -2.06M | -8.10M | -4.05M | -2.23M | -7.73M | -1.06M | — | — | — | — |
| Other Financing Charges | -60,000 | — | -1.17M | -35,000 | -329,000 | -2.26M | -50,000 | -120,000 | 10.42M | 3.52M | -99,000 | -127,000 | -81,000 | -68,000 | — | — | — | — | — | — |
| Financing Cash Flow | -7.61M | -13.10M | -20.00M | 175.23M | 10.51M | 91.78M | -3.75M | 22.74M | 11.26M | 66.33M | 24.32M | 1.38M | 2.59M | -1.80M | -947,344 | 5.04M | 15.42M | 92,470 | 43.22M | 89,183 |
| Other Cash Details | ||||||||||||||||||||
| End Cash Position | 84.31M | 58.10M | 43.65M | 41.94M | 28.48M | 32.23M | 21.81M | 24.21M | 23.76M | 28.38M | 14.89M | 7.75M | 9.76M | 4.23M | 8.91M | 11.45M | 13.00M | 14.89M | 27.43M | 5.18M |
| Income Tax Paid | 395,000 | 192,000 | 190,000 | 217,000 | 259,000 | 65,000 | 37,000 | 30,000 | 20,000 | 146,000 | 30,000 | 14,000 | 30,000 | 30,000 | 17,300 | 14,000 | — | — | — | — |
| Interest Paid | 6.38M | 4.27M | 4.22M | 4.37M | 3.72M | 3.87M | 2.00M | 1.51M | 232,000 | 115,000 | 473,000 | 607,000 | 405,000 | 418,000 | 460,927 | 127,656 | — | — | — | — |
| Free Cash Flow | -37.51M | -39.02M | -23.53M | -25.13M | -27.99M | -10.38M | -15.33M | -22.81M | -31.84M | -30.81M | -8.09M | -4.92M | -3.51M | -1.85M | -940,511 | -7.46M | -11.16M | -14.15M | -9.57M | -5.31M |
Top Institutional Holders
| Holder | Date Reported | Shares | Value | % Held |
|---|---|---|---|---|
| Delaware Group Equity Fds V-Small Cap Core Fund | Nov 30, 2024 | 1,946,161 | 80.43M | 3.99% |
| Roxbury/Hood River Small Cap Growth Fund | Oct 31, 2024 | 1,575,167 | 65.10M | 3.23% |
| Vanguard Total Stock Market Index Fund | Sep 30, 2024 | 1,477,680 | 61.07M | 3.03% |
| iShares Russell 2000 ETF | Nov 30, 2024 | 1,322,678 | 54.67M | 2.71% |
| Vanguard Small-Cap Index Fund | Sep 30, 2024 | 1,159,702 | 47.93M | 2.38% |
| AB Cap Fd.-AB Small Cap Growth Port | Dec 31, 2024 | 1,153,398 | 47.67M | 2.37% |
| Advisors Inner Circle Fund II-Champlain Small Company Fund | Sep 30, 2024 | 1,030,000 | 42.57M | 2.11% |
| AB Discovery Growth Fund | Dec 31, 2024 | 834,518 | 34.49M | 1.71% |
| Old Westbury Small & Mid Cap Strategies Fund | Oct 31, 2024 | 835,000 | 34.51M | 1.71% |
| Vanguard Extended Market Index Fund | Sep 30, 2024 | 746,292 | 30.84M | 1.53% |
Article
Will AtriCure (ATRC) Report Negative Earnings Next Week? What You Should Know
AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Feb 5, 2025
Article
AtriCure to Announce Fourth Quarter and Full Year 2024 Financial Results
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its fourth quarter and full year 2024 financial results on Wednesday, February 12, 2025. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Wednesday, February 12, 2025, to discuss its fourth quarter and full year 2024 fin.
Jan 22, 2025
Article
AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2024, Provides Financial Outlook for 2025, and Announces Upcoming Analyst & Investor Day
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced preliminary financial results for the fourth quarter and full year 2024 and provided 2025 financial guidance. Additionally, AtriCure announced that it will host an Analyst & Investor Day at its headquarters in Mason, Ohio on Wednesday, March 26, 2025. Pr.
Jan 13, 2025
